News

AcuCort AB (publ) publishes its Annual Report January 1, 2020 – December 31, 2020

6 april, 2021

AcuCort AB’s Annual Report 2020 (in Swedish). [Läs mer]

AcuCort: Granted patent in Japan for the company’s drug ISICORT®

30 mars, 2021

AcuCort AB (Spotlight Stock Market: ACUC) today announced that the Japan Patent Office (JPO) has granted a patent... [Läs mer]

AcuCort is granted trademark protection in the US for its drug ISICORT®

3 mars, 2021

AcuCort AB (Spotlight Stock Market: ACUC) today announced that the United States Patent and Trademark Office (USPTO) has... [Läs mer]

AcuCort’s drug ISICORT® is approved for treatment of COVID-19

3 februari, 2021

AcuCort AB (Spotlight Stock Market: ACUC) today announced that the Swedish Medical Products Agency has granted the company’s... [Läs mer]

AcuCort is granted a patent in China for the drug ISICORT®

3 november, 2020

AcuCort AB (Spotlight Stock Market: ACUC) today announced that the China National Intellectual Property Administration has granted the... [Läs mer]

AcuCort receives market approval from the Swedish Medical Products Agency for the drug ISICORT®

7 oktober, 2020

AcuCort AB (Spotlight Stock Market: ACUC) has today received the market approval from the Swedish Medical Products Agency... [Läs mer]

AcuCort appoints Jonas Jönmark as new CEO ​​​​​​​

16 juli, 2020

AcuCort AB (Spotlight Stock Market: ACUC) today announces that the company has finalized the process to recruit a... [Läs mer]

AcuCort confirms good progress in ISICORT® national application process ​​​​​​​

15 juli, 2020

AcuCort AB (Spotlight Stock Market: ACUC) received the Second Round Assessment Report from the Swedish MPA as planned... [Läs mer]

AcuCort accelerates recruitment of a permanent CEO

15 juni, 2020

AcuCort AB (Spotlight Stock Market: ACUC) announces today that the company’s interim CEO Ann Gidner ends her employment... [Läs mer]

AcuCort comments on the status update regarding the second US patent application  

28 maj, 2020

AcuCort AB (Spotlight Stock Market: ACUC) has noted an updated status regarding its second patent family application for... [Läs mer]